New study finds Ozempic and Mounjaro protect the heart too
7 Articles
7 Articles
A new study suggests that the use of Mounjaro in patients with type 2 diabetes could reduce the risk of myocardial infarction in people suffering from cardiovascular disease. Patients who received this treatment had a 33% lower risk of having a heart attack compared to those treated with another medicine used in type 2 diabetes.
MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients
Treatment with GLP-1 drugs is well established to have a positive effect on patients with type 2 diabetes and overweight. Many patients with these conditions also present with cardiovascular disease symptoms. While GLP-1 drug treatment has shown improvements, there is little evidence directly comparing the impacts of these drugs, including tirzepatide (marketed as Mounjaro) with the current standard of care for cardiovascular disease to reduce t…
How safe are Ozempic and Wegovy? Researchers have evaluated patient data and discovered a previously neglected effect.
New study finds Ozempic and Mounjaro protect the heart too
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% reduction in major cardiovascular events, confirming powerful heart-protective effects…
A new study suggests that the administration of the medicine to patients with type 2 diabetes mellitus could reduce the risk of myocardial infarction in people suffering from cardiovascular disease.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
